Australian antibiotic developer Recce Pharmaceuticals has turned to Asia to secure strategic investors to help with funding and, more pertinently, to potentially achieve local market penetration.

According to Recce’s executive director James Graham this turn to Asia is born out of two drivers. “There’s the patient population which will lead to consumer demand and Asia provides access to smart, patient capital," he says.